New Novus (300765.SZ) subsidiary Secuchiumab Injection Phase III clinical trial obtained top-line analysis data

According to the Zhitong Finance App, Sinovay (300765.SZ) announced that the scuchiyumab injection developed by the company's holding subsidiary Shiyumab Group Jushi Biopharmaceutical Co., Ltd. (“Jushi Bio”) recently obtained top-line analysis data in a phase III clinical trial.

This product is an all-human IgG1 monoclonal antibody developed by Jushi Biotech and is a biosimilar to Kesanting®. The approved indications for Kesanting® in China include plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa in the age of 6 and above, and its efficacy and safety have been widely recognized.

The key study has reached the pre-set main end point and obtained positive top-line results. Statistical analysis shows that the product is clinically equivalent to Kesanting® and has good safety. There are no new or unexpected safety signals, and it is expected to meet the safety requirements of patients for long-term medication use. Detailed data will be published in subsequent academic conferences and journals.